

The African swine fever virus lectin EP153R modulates the surface membrane expression of MHC class I antigens

Carolina Hurtado · Maria José Bustos · Aitor G. Granja · Patricia de León · Prado Sabina · Eduardo López-Viñas · Paulino Gómez-Puertas · Yolanda Revilla · Angel L. Carrascosa

Received: 7 September 2010 / Accepted: 20 October 2010 / Published online: 11 November 2010
© Springer-Verlag 2010

Abstract We have modeled a 3D structure for the C-type lectin domain of the African swine fever virus protein EP153R, based on the structure of CD69, CD94 and Ly49A cell receptors, and this model predicts that a dimer of EP153R may establish an asymmetric interaction with one MHC-I molecule. A functional consequence of this interaction could be the modulation of MHC-I expression. By using both transfection and virus infection experiments, we demonstrate here that EP153R inhibits MHC-I membrane expression, most probably by impairing the exocytosis process, without affecting the synthesis or glycosylation of MHC antigens. Interestingly, the EP153-mediated control of MHC requires the intact configuration of the lectin domain of the viral protein, and specifically the R133 residue. Interference of EP153R gene expression during virus infection and studies using virus recombinants with the EP153R gene deleted further support the inhibitory role of the viral lectin on the expression of MHC-I antigens.

Introduction

Virus infection of susceptible organisms may trigger a cascade of mechanisms designed to minimize the cytopathogenicity and spread of the invading virus. The induction of cytokines and activation of cytotoxic T lymphocytes (CTLs), as well as the natural killer (NK) cell response and the generation of antibodies, play a critical role in the innate and adaptative immune response of the infected host. Furthermore, control of the cell cycle and apoptosis, frequently mediated by p53, have also been described as tools in the defense of cells against virus infections. Upon infection, viral proteins are processed into small peptides by the proteasome and transported to the lumen of the endoplasmic reticulum (ER), where they associate with molecules of the class I major histocompatibility complex (MHC-I). The resulting complex then leaves the ER and is conducted, via the Golgi apparatus, to the surface of the cell, where it can be recognized by receptors on CTLs and NK cells. While the interaction of MHC-I molecules with CTL receptors stimulates cytotoxic activity against the infected cells, the lytic function of NK cells is inhibited by the binding of human leukocyte antigen class I (HLA-E) to inhibitory receptors belonging to C-type lectin-like protein families, which are expressed in the membranes of NK cells.

Therefore, one of the most effective and well-established defenses against the host immune response by viruses is the down-modulation of MHC-I expression [1], thus impairing the presentation of viral antigens to T lymphocytes. Moreover, as in the case of cytomegalovirus infection, the down-regulation of MHC-I expression, which should enhance the recognition of virus-infected cells by NK cells, is counteracted by the action of several virus proteins (US2, US3, US6, US11, UL16, UL18, UL40, etc.), which interfere with

C. Hurtado · M. J. Bustos · P. de León · P. Sabina · P. Gómez-Puertas · Y. Revilla · A. L. Carrascosa (✉)
Centro de Biología Molecular “Severo Ochoa”,
(C.S.I.C.-U.A.M.) Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid,
28049 Madrid, Spain
e-mail: acarrascosa@cbm.uam.es

A. G. Granja
Lymphocyte Interaction Lab, Cancer Research UK London
Research Institute, Lincoln’s Inn Fields Laboratories,
44 Lincoln’s Inn Fields, London WC2A 3PX,
United Kingdom

E. López-Viñas
Biomol-Informatics SL, Parque Científico de Madrid,
Campus de Cantoblanco,
28049 Madrid, Spain

different steps in the normal pathway of antigen presentation (reviewed in [2]).

African swine fever virus (ASFV) is the sole member of the family *Asfarviridae* and of the genus *Asfivirus*, as recognized in the Eighth Report of the International Committee on Taxonomy of Viruses. The virus produces an important disease in domestic pigs and can be maintained in a sylvatic cycle between wild swine and argasid ticks of the genus *Ornithodoros*. Highly lethal to subclinical disease forms have been described in ASFV infection of both wild and domestic swine, and these differences may depend on the contribution of different viral and host factors. Several ASFV genes are able to modulate the host defence mechanisms (A238L, A179L, A224L, EP402R, EP153R,...), interfering with cellular transcription factors or with the induction of programmed cell death after ASFV infection (reviewed in [3]). The open reading frame EP153R of ASFV encodes a non-essential protein that has been shown to be involved in the control of the apoptotic process induced in ASFV-infected cells [4]. Comparison of this sequence with data available in the literature has revealed the existence of a region in the viral protein that is homologous to C-type lectins. Protein EP153R presents an intracellular N-terminal domain, a hydrophobic segment that is probably inserted in the plasma membrane, and an extracellular region that contains the C-type lectin domain.

Crystallographic models of several C-type lectin molecules, such as CD94, Ly49A and CD69 [5–7], have allowed us to model the three-dimensional (3D) structure of the ASFV lectin in parallel with those described for the inhibitory NK cell receptors and thereby to investigate the possible interaction between pEP153R and MHC-I molecules. The modeling of the pEP153R molecule as a dimer, points to a possible interaction with MHC-I antigens on the basis of the previously known interaction between the NK cell C-type lectin-like receptor NKG2D and its MHC-I-like ligand ULBP3. Here, using swine, mouse and human cell lines ectopically expressing EP153R, we describe a significant down-regulation of MHC-I expression. Importantly, the inhibition of MHC-I expression detected in the plasma membrane requires the intact configuration of the lectin domain of the EP153R gene, and specifically the conservation of its arginine 133 residue. Furthermore, the presence of EP153R did not affect the synthesis, maturation or degradation of the nascent MHC-I molecules but inhibited the process of exocytosis of these molecules from the ER to the cell membrane. Finally, increased expression of MHC-I antigens was observed when the EP153R gene was inhibited by specific siRNA transfection during ASFV infection, while studies with ASFV recombinants with the EP153R gene deleted also revealed a higher level of expression of SLA-I in the plasma membrane during infection of porcine cells in the absence of EP153R transcription.

Materials and methods

Cells and viruses

Vero (African green monkey kidney), Raw (murine macrophages) and Jurkat (human leukemia T cell line) cells were obtained from the American Type Culture Collection. The established cell line IPAM, derived from swine alveolar macrophages [8], was obtained from Dr. M. Parkhouse, Instituto Gulbenkian de Ciencia, Portugal. Vero and COS-1 cells were grown in Dulbecco's modified eagle medium (DMEM; GIBCO) supplemented with 5% fetal calf serum (FCS). IPAM, Raw and Jurkat cell cultures were grown in RPMI 1640 medium supplemented with 10% FCS. All media were supplemented with 2 mM L-glutamine, 100 U of gentamicin per ml and non-essential amino acids. Cells were grown at 37°C in 7% CO₂ in air saturated with water vapor. Jurkat cells were stimulated with phorbol 12-myristate 13-acetate (PMA; Sigma) at 15 ng/ml and A23187 calcium ionophore (Ion; Sigma) at 1 μM (PMA/Ion) when required.

The Vero-adapted ASFV strain BA71 V and the WR strain of vaccinia virus were propagated and titrated by plaque assay on Vero cells as described elsewhere [9, 10]. The virulent field isolates E70 and Uganda 59 of ASFV [11, 12] were grown and assayed on cultures of swine macrophages [9] or in COS-1 cells as described previously [13]. The construction and characterization of an ASFV deletion mutant lacking the EP153R gene (Δ EP153R) from the Vero-adapted BA71 V virus strain has been reported previously [14]. A new virus recombinant lacking the EP153R gene was generated from the E70 ASFV isolate by *in vivo* homologous recombination, using a previously described deletion plasmid (p Δ EP153R) [14] that was designed to facilitate the replacement of a genomic DNA fragment of 333 bp covering the majority of EP153R and contained a marker gene, LacZ, under the control of the ASFV promoter p72. The construction, selection and purification of the deletion mutant virus clones was performed as described previously [14, 15]

Virus infections were performed at 37°C. Briefly, Raw or IPAM cell cultures were infected with the corresponding virus in a small volume of culture medium containing infective virus to obtain a multiplicity of infection (moi) of 3 plaque-forming units (pfu) per cell. After 1.5 h of adsorption, the non-adsorbed virus was removed, fresh culture medium was added, and the cultures were incubated further at 37°C for the times indicated.

EP153R-derived constructs

EP153R (whole gene or derived constructs) was subcloned into the pcDNA3.1 Myc/His mammalian expression vector (Invitrogen). Two constructs were first generated from the

EP153R gene: one (“lectin C”) containing the whole lectin-C domain (sequence from Trp51 to Lys153) but not the intracellular region of the molecule, and the other (“trunc lectin C”) with the same domain lacking the last 5 amino acids in the carboxyl end of the molecule (sequence Trp51-Leu148). This deletion included the Cys151 that may be involved in a disulfide bond with Cys97, which is critical for maintaining the 3D structure of the lectin domain. The whole EP153R gene or fragments derived from this gene were PCR-amplified using oligonucleotides that included the BamHI and EcoRI restriction sites to facilitate cloning into the pcDNA3.1 Myc/His plasmid.

The oligonucleotides used for the whole EP153R gene were

5'-CGCGGATCCATGTATTTTAAGAAAAAATAC-3' and 5'-CGCGAATTCCATTATTTACCACAAATAAAT-3', the oligonucleotides used in the “lectin C” construct were 5'-CGCGGATCCATGTGGGATAATTATATAAAA-3' and 5'-CGCGAATTCCATTTACCACAAATAAAA-3', and the oligonucleotides used in the “trunc lectin C” construct were 5'-CGCGGATCCATGTGGGATAATTATATAAAA-3' and 5'-CGCGAATTCCATAATAATAAATCTGTAT-3'.

We also generated two additional constructs (“R133D” and “R133 K”) by site-directed mutagenesis of the Arg133 codon of the full-length EP153R gene, replacing it with aspartic acid or lysine in the pcDNA-EP153R plasmid (50 ng), using the following primers:

R133D:

forward (5'-CAATACGGTAATATTAGATGGTGATAATAAATATAGTC-3')

reverse (5'-ATTTATTATCACCATCTAATATTACCGTATTGTTAACCC-3');

R133 K:

forward (5'-CAATACGGTAATATTTAAAGGTGATAATAAATATAGTC-3')

reverse (5'-ATTTATTATCACCATTTTATATTACCGTATTGTTAACCC-3').

The PCR reaction was performed with 2 units of the enzyme Pfu DNA polymerase (Promega) by 16 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 45 s, and extension at 68°C for 10 min. The constructs were digested with 10 units of DpnI (Promega), and 3 µl was used to transform competent *E. coli* JM109 cells. The clones were then sequenced to confirm the mutagenesis.

The EP153R gene was also cloned into the pEGFP-C2 plasmid to generate the ASFV lectin gene fused to the green fluorescent protein gene (pEGFP-EP153R). EP153R gene was PCR-amplified by using two oligonucleotides that included the Hind III and EcoRI restriction sites to facilitate cloning into the pEGFP-C2 plasmid. These oligonucleotides were 5'-CGCAAGCTTGATGTATTTTAAGAAAAAATACATCGG-3' and 5'-CGCGAATTCTTATTACCACA AATAGATAATAA-3'.

Transfections

For transient expression, cells were plated at 1×10^6 cells per 6-cm dish 24 h before being transfected with 2 µg of the corresponding plasmid, using 12 µl of Lipofectamine (2 mg/ml; Invitrogen) per dish. To generate stably expressing lines, cells were transfected as described above, incubated for 2 days before being trypsinized, and plated at 1:10 dilution in 10-cm dishes. The following day, antibiotic selection was applied (500 µg/ml G418; Sigma), and cells were refed with the medium and fresh antibiotic every 3 days until colonies were apparent (2-3 weeks).

Expression of MHC-I antigens by flow cytometry

The expression of MHC-I antigens in cellular plasma membranes was analyzed by flow cytometry. Cultures of IPAM, Raw or Jurkat cells were washed with PBS-staining buffer (1% BSA, 0.01% NaN₃, 1% FCS and 5 mM EDTA in PBS) before being incubated with porcine IgG (0.2 mg/ml; Sigma-Aldrich) for 10 min at 4°C to block Fc receptors. Cells were washed again with PBS-staining buffer and incubated for 30 min in the dark with the specific antibody to porcine SLA-I or SLA-II antigens (BL6H4, 4B7/8 and JM1E3 for SLA-I, or BL2H4 for SLA-II; monoclonal antibodies kindly provided by Dr. Diego Llanes, Universidad de Cordoba, Spain, diluted 1/10 in PBS-staining buffer), to murine MHC-I antigens (from Serotec, diluted 1/100 in PBS-staining buffer) or to human MHC-I antigens (supernatant of W6/32 hybridoma [16], at a concentration of 50 µl/10⁶ cell) or to human ICAM-1 (PE antihuman CD54, Pharmingen, diluted 1/50). After incubation (except for the PE-labeled human ICAM antibody) under similar conditions with the secondary antibody (specific for mouse IgG; Alexa 488 from Molecular Probes, diluted 1/500), samples were washed and suspended in PBS-staining buffer at 4°C in the dark. Propidium iodide was used to exclude dead cells by incubation of the samples with the vital dye at a concentration of 1 µg/ml for 30 min at room temperature before analysis of the labeled populations in a FACSCalibur flow cytometer.

Maturation and exocytosis of MHC-I antigens

The maturation of MHC-I molecules was evaluated by determining their increased resistance to endoglycosidase H (Endo H) cleavage. To perform this analysis, Jurkat cells (20×10^6) pre-stimulated with PMA/Ion as indicated above, were incubated in methionine/cysteine-free DMEM supplemented with 10% FCS for 45 min at 37°C, pulse-labeled at 37°C for 15 min with 1000 µCi/ml [³⁵S]methionine-cysteine (Protein Labeling Mix, Perkin Elmer) in the same medium, and chased with complete RPMI 1640 medium supplemented with 1 mM cold methionine and cysteine at

37°C for the indicated time. At different times, cells were spun down, resuspended in 50 µl of PBS, frozen in liquid nitrogen, and stored at -80°C. Cells were lysed in Nonidet P-40 lysis buffer (0.5% Nonidet P-40, 50 mM Tris-HCl pH 7.5, 5 mM MgCl₂) containing a mixture of protease inhibitors (complete-mini, Roche). Lysates were centrifuged at 14,000 rpm for 10 min at 4°C, pre-cleared three times for 60 min with CL-4B beads (Sigma-Aldrich) and 3 µl of normal mouse serum, and immunoprecipitated with W6/32 monoclonal antibody (0.05 µg/ml) and protein A-Sepharose beads (Sigma-Aldrich). Immunoprecipitates were normalized to equal TCA-precipitable ³⁵S-labelled protein, washed three times with Nonidet P-40 washing buffer (0.5% Nonidet P-40, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA) and analyzed by SDS-PAGE in 10% acrylamide gels. Endo H (New England Biolabs) was added to the immunoprecipitates according to the manufacturer's instructions. Protein bands were visualized by autoradiography and quantified after scanning using TINA 2.09e software.

Exocytosis of MHC-I antigens was evaluated by detecting the molecules that were newly incorporated into the plasma membrane. Stably-transfected Jurkat cells (6.5 × 10⁶) that had been pre-stimulated by PMA/Ion for 15 min as indicated above were incubated with an excess of W6/32 monoclonal antibody (250 µg/ml) for 60 min at 4°C. Cells were washed twice with cold PBS and incubated at 37°C for different times. At each time point, cells were transferred at 4°C to stop exocytosis, and the expression of new MHC-I molecules in the plasma membrane was detected by flow cytometry with W6/32 monoclonal antibody conjugated with FITC.

Confocal microscopy

The localization of EP153R was studied by confocal microscopy. Vero cells were grown on cover slips to 2 × 10⁵ cells/cm² before transfection with the plasmid pEGFP-EP153R described above. Cultures were rinsed three times with PBS and fixed with cold 99.8% methanol (Merck) for 15 min at -20°C before being rehydrated twice with PBS and blocked with 1% bovine serum albumin in PBS for 10 min at room temperature. The cells were then incubated with an antibody specific for either human PDI (ER resident protein, from Sigma-Aldrich), mannosidase II (Golgi marker, from Chemicon) or CD63 (lysosomal marker, from DSHB), diluted 1/100 in PBS for 2 h, rinsed extensively with PBS, and incubated with the corresponding secondary antibody (goat anti-rabbit or mouse Alexa 594; Molecular Probes, diluted 1/500 in PBS) for 1 h at room temperature in the dark. One culture was incubated with 1-2 µM MitoTracker Red CM-H2Ros (Invitrogen) for 1 h to stain

mitochondria before being collected, without antibody incubation, in parallel with the rest of the cultures. Finally, the cells were rinsed successively with PBS, distilled water and ethanol and mounted with a drop of Mowiol (Dabco) on a microslide. Visualization of the stained cultures was performed under a fluorescence Axioskop 2 plus (Zeiss) microscope coupled to confocal Microradiance (Bio-Rad) equipment. The images were digitalized and processed with Metamorph, Lasershop 2000.

Silencing of the viral EP153R gene by specific siRNAs

Pre-designed siRNA specific for the EP153R gene was obtained from Gene Link (Ref 27-6430-05). Two siRNA duplexes were used, with the following sequences:

siRNA #1: EP153R-113S: 5'-GAACUAAUAUGAUA ACUCUTT

EP153R-113AS: 5'-AGAGUUAUCAUAUUAGUU CTT

siRNA#2: EP153R-361S: 5'-CAAUCUAUGUAUUG GGUUAATT

EP163R-361AS: 5'-UAACCCAAUACAUAAGAUUG TT

Cells were transfected with a mixture (1:1) of siRNA duplexes (60 nM) using Lipofectamine 2000 (Invitrogen) protocols and infected, 20 to 24 h after transfection, with ASFV. At different times after infection, cells were collected to analyze SLA-I expression by flow cytometry as described above, and EP153R mRNA transcription by RT-PCR.

RT-PCR analysis of mRNA expression

For this analysis, total RNA was isolated using TRIzol reagent (Invitrogen), pre-treated (1 µg) with RQ1 DNase (Promega) to eliminate ss and ds contaminant DNA and reverse-transcribed to single-stranded cDNA using a Revertaid H Minus First Strand cDNA synthesis kit (Fermentas), following the manufacturer's recommendations. The DNA was PCR-amplified with AmpliTaq DNA polymerase (Roche) and the following primers: for EP153R whole-gene and derived constructs:

5'-GGGATAATTATATAAAAATGTTACCG (forward) and

5'-GACTATATTTATTATCACCACGTAAT (reverse), and for the p72 gene,

5'-CGCGGATCCATGGCATCAGGAGGAG (forward) and

5'-CGCGAGATCTAGCTGACCATGGGCC (reverse).

The PCRs were performed after denaturation at 94°C for 5 min, by 25 cycles of denaturation at 94°C for 30 s,

annealing at 55°C for 30 s and extension at 72°C for 30 s, followed by a last incubation at 72°C for 10 min. Amplified cDNAs were analyzed by electrophoresis on 1% agarose gels containing ethidium bromide.

Homology modeling procedures

Structural models for the EP153R dimer and SLA-I molecules were built using homology modeling procedures. Sequences belonging to the families of EP153R-ASFV and swine SLA-I were obtained from databases using BLAST [17] with an E-value cut-off of 10^{-5} and aligned using ClustalW [18]. To ensure correct gap positioning, multiple alignments were re-evaluated using TCOFFEE [19]. Sequence-to-structure alignments were performed using the threading server Phyre [20], an improved version of 3D-PSSM [21], against the SCOP database [22]. The crystallographic coordinates of human CD69 antigen dimer (Protein Data Bank entry 1E8I [7]; 54% sequence similarity), human CD94 monomer (1B6E [5]; 47% sequence similarity) and murine NK receptor Ly49A dimer (1QO3 [6]; 37% sequence similarity) were structurally aligned using Dali [23] prior to being used as templates for the construction of the 3D model for the lectin domains of the EP153R dimer. Transmembrane domains of EP153R were modeled using the threading server Phyre [20], selecting the 2RLF structure (Influenza A M2 transmembrane domain; 47% sequence similarity) as the template. The structure for the swine SLA-I molecule (UniProt/TrEMBL entry Q8MHT7_PIG) was modeled using murine MHC -I coordinates (PDB entry 1S7U [24]) as a template (74% sequence similarity and Blast E-value 7.7×10^{-108}). Structural 3D models were built using the SWISS-MODEL server [25–27] facilities at <http://swissmodel.expasy.org/SWISS-MODEL.html>, and their structural quality was checked using the analysis programs provided by the same server (Anolea/Gromos/Verify3D). The model for the interaction between the EP153R dimer and SLA-I, as well as for fine positioning of the amino acids in the interface of both molecules, was also constructed by homology modeling. As a template, we used the co-crystal structure of the activating NK receptor, NKG2D, in a complex with the MHC-I-like molecule ULBP3 (PDB entry 1KGC [28]). Finally, both for individual structures and for the whole complex, in order to optimize geometries, release local constraints and correct possible inappropriate contacts, the modeled assemblies were energy minimized through implementation of the GROMOS 43B1 force field in the program DeepView [29], using 500 steps of steepest-descent minimization followed by 500 steps of conjugate-gradient minimization.

Results

Modeling of the EP153R dimer and its interaction with SLA-I

EP153R exhibits sequence similarity to swine CD69 antigen and sequence-to-structure compatibility with some C-type lectin-like domains (CTLDs; all of which lack the Ca^{2+} binding site involved in sugar recognition in canonical C-type lectins) of proteins related to CD69. These characteristics prompted us to generate a 3D model for the whole EP153R protein, based on the crystallographic coordinates of some CTLDs available in databases, such as those of human CD69 [7], human CD94 [5] and murine Ly49A [6]. Structure-based alignment (Fig. 1a) showed that most of the elements present in CD69 and related proteins are also conserved in EP153R. As indicated in the figure, a non-structured N-terminal segment (residues 1–30) is followed by a predicted transmembrane alpha helix with amphipathic characteristics spanning residues 30 to 49. Finally, after a 20-amino-acid-long unstructured region, the protein exhibits a high structural correspondence to the lectin domain of the aforementioned membrane antigens, with the exception of a non-structured loop present in CD69, CD96 and Ly49A, which is not found in EP153R (the large gap between Val126 and Asn127 in the alignment shown in Fig. 1a). The 3D structure of the lectin domain is maintained by the presence of several disulfide bonds between Cys residues conserved in the aligned sequences. In EP153R, there are only two Cys-Cys bonds (Cys67-Cys78 and Cys97-Cys151; Fig. 1c). A third bond in the three template lectins (Cys residues aligned to EP153R Thr129 and Val142, respectively) is used in those proteins to maintain the structure of the loop that is not present in EP153R. The positions within the alignment of the Cys residues indicated above are conserved in all of the proteins, with the exception of the one corresponding to Cys67 in the Ly49A sequence, which is substituted by a glycine. In this last case, the disulfide bond is established between a Cys located 9 positions downstream and only present in Ly49A. The structure of human CD94 is also maintained by a fourth additional disulfide bond between Cys59 and Cys70, which are not present in the rest of the aligned proteins. Despite these small differences, the overall structure of CD69, CD94 and Ly49A (Fig. 1d) is almost identical to that of the EP153R protein (Fig. 1c), with the exception of the missing loop.

The dimer structure of EP153R (Fig. 1b) was predicted on the basis of the dimeric nature of the crystallized antigens used as templates, in addition to the complementary features of the helix-H3 and beta strand-E1 structural elements involved in the dimerization surface of all members





Fig. 1 Structural model for the EP153R dimer. **(a)** Structure-based alignment of proteins used as templates for the dimerized lectin domain of EP153R: human CD69, human CD94 and murine Ly49A antigens (PDB entries 1E81, 1B6E and 1QO3, respectively). The sequence of swine CD69 has been included to illustrate the similarity between the EP153R and CD69 antigens. The location of predicted secondary structure elements in the EP153R model (TM: transmembrane, H: alpha-helix and E: beta-strand) as well as the two Cys-Cys bonds (open and black circles, respectively) are also indicated. Dotted lines indicate the location of coil elements whose structure has been modeled in the absence of suitable templates. **(b)** Surface, colored by charge, and ribbon-plot representation of the relative position of the two molecules of EP153R in the dimerized complex. The situation of secondary structure elements is indicated. Note the absence of

electrostatic charge on the surface corresponding to the hydrophobic transmembrane helix (H1-TM). **(c)** Detail of the lectin domain (residues 64 to 153) in the EP153R model. Cys67-Cys78 and Cys97-Cys151 disulfide bond residues are depicted. **(d)** Structural alignment of CD69 (dark blue), CD94 (light blue) and Ly49A (green) lectin domains, showing the similarity among them and to the modeled EP153R lectin structure (red). The location of an extra loop not present in EP153R is indicated (red circle). **(e)** Detail of the modeled transmembrane segment of EP153R. Side chains of polar residues from both helices are oriented toward the inner face of the dimer (green spheres), while the hydrophobic amino acids (yellow) are oriented toward the membrane environment. Plots were generated using PyMOL (DeLano Scientific, San Carlos, CA)

Fig. 2 Structural model for EP153R-SLA I interaction. **(a)** Ribbon-plot representation of the relative position of the two proteins. The groove domain (yellow/orange) of the SLA-I heavy chain model comes into contact with the lectin domains (blue and green) of the EP153R dimer. **(b)** Detail of the interaction area, illustrating the asymmetric contribution of the two lectin domains of the two EP153R monomers. Also indicated is the position of helix H3 and beta strand E1, whose residues putatively help maintain the stability of the EP153R dimer. **(c)** Diagram indicating the surface complementarity of the interacting molecules. Bottom panel: position of residues in SLA-I and EP153R molecules predicted to be involved in protein contact



of this protein family [5–7]. Modeling of the transmembrane helix (H1-TM; Fig. 1e) showed a nearly amphipathic distribution of residues, with the polar ones facing the same side of the structure. Due to the hydrophobic membrane environment, we suggest that these polar residues are arranged in a low-energy conformation, thus helping dimer stability. A putative role for Cys15 and/or Cys29, both located in the cytoplasmic part of the molecule, in the stabilization of the dimer structure cannot be inferred.

A possible interaction between an MHC-I molecule (SLA-I) and the EP153R dimer was modeled (Fig. 2a) on the basis of the known structure of the interaction between the NK cell C-type lectin-like receptor NKG2D and its

MHC-I-like ligand ULBP3 [28]. As shown in Fig. 2, the groove region of the predicted model for the heavy chain of swine SLA-I (based, in turn, on the known structure of murine MHC-I [24]) is in contact with the lectin “heads” of the dimerized EP153R structure. As in the template [28], the interaction is not symmetrical, implying different surface patches for the two EP153R lectin domains (Fig. 2b-c). Interestingly, and similar to the NKG2D-ULBP3 interaction, both surfaces exhibit reasonable complementarities in terms of electrostatic properties (Fig. 2c), mainly involving patches of polar residues. As shown in Fig. 2c, surface atoms from residues Ile87, Arg176, Ser179 and Leu184 of swine SLA-I are in contact with the area defined by

residues Asn121, Arg133 and Asp135 in one EP153R monomer. In parallel, the surface patch comprising residues Glu90, Gln93, Thr94, Arg96 and Val97 of SLA-I lies on the area delineated by amino acids Asn121, Ser122, Met123, Arg133, Asp135, Asn136 and Tyr138 of the accompanying EP153R monomer.

EP153R down-regulates MHC-I expression both in porcine and human cells

To determine a possible effect of the viral gene EP153R on the expression of porcine SLA-I antigens, IPAM macrophage-derived cells were stably transfected with EP153R or the control pcDNA plasmid as indicated in [Materials and methods](#). Both cell lines and parental untransfected IPAM cells were analyzed by flow cytometry to determine the expression of SLA-I and SLA-II in the plasma membrane using specific antibodies. As shown in [Fig. 3a](#), the parental and pcDNA-transfected cells exhibited similar levels of SLA-I expression, while a significant reduction (around 50%) was observed in IPAM cells expressing the EP153R gene. Interestingly, the expression of SLA-II antigens was similar in all the cell lines, indicating that the down-regulation detected in the plasma membrane is specific for SLA-I antigens.

We next extended these studies to other cells in order to determine if the EP153R gene might produce an inhibitory effect on MHC-I expression in human cells, similar to that observed in porcine cells. To this end, parent human Jurkat cells or cells that were stably transfected with either EP153R or the control pcDNA plasmid were incubated with anti-CD54 or anti-HLA-I (W6/32) antibody and analyzed by flow cytometry. [Fig. 3b](#) shows that the intensity of human MHC-I expression was markedly reduced in Jurkat cells transfected with EP153R as compared to the levels obtained in the control cultures (parental cell line or cells transfected with the control pcDNA plasmid). The specificity of the inhibitory effect was assessed by analyzing the expression of a different cell-surface component, in this case, ICAM-1, a glycoprotein belonging to the immunoglobulin superfamily of adhesion molecules. The results showed that ICAM-1 expression was not affected by the presence of the EP153R gene ([Fig. 3b](#)), which again supports the idea that the viral lectin specifically inhibits the expression of MHC-I antigens. The control of expression of EP153R-specific mRNA performed by RT-PCR in the stably-transfected IPAM and Jurkat cell lines showed that the virus lectin was only transcribed in cells transfected by the EP153R gene ([Fig. 3c](#)).




Fig. 3 Modulation of MHC-I expression by EP153R-derived constructs. **(a)** Inhibition of porcine SLA-I and SLA-II expression by EP153R. IPAM cell cultures stably-transfected, or not, with pcDNA or EP153R, were incubated with specific antibodies against porcine SLA-I or SLA-II antigens (BL6H4 or BL2H4, respectively) to analyze its expression in the plasma membrane by flow cytometry. The percentage of antigen expression is shown (mean \pm S.D. in duplicate samples), taking the value in parental IPAM cells as 100%. **(b)** Inhibition of human MHC-I expression by EP153R. Cultures of

Jurkat cells, either parental (Jurkat) or stably-transfected with pcDNA (JpcDNA) or EP153R (JEP153R), were incubated with a specific antibody against human MHC-I (W6/32) or ICAM-I (CD54) to detect the expression of these molecules in the plasma membrane by flow cytometry. The intensity of the antigen expression is shown (mean \pm S.D. in duplicate samples), representing the results obtained in two independent experiments. **(c)** The mRNA transcription specific for the EP153R gene was assayed in stably transfected Jurkat and IPAM cell lines by RT-PCR

The inhibition of MHC-I expression in human cells requires the intact configuration of the lectin domain of the EP153R gene and, specifically, of the R133 residue.

To evaluate the importance of different regions of the ASFV lectin in the inhibition of MHC-I expression, we generated four EP153R-derived constructs as detailed in **Materials and methods**: two of them contained only the lectin-C domain (without the intracellular region of the

molecule), either complete (“Lectin C”, Fig. 4a) or with the last 5 amino acids deleted from the carboxy terminus of the molecule (“trunc Lectin C”), while the other constructs contained the whole EP153R gene with the Arg133 residue replaced either by aspartic acid or lysine (“R133D” and “R133 K”, respectively, Fig. 4a). Transiently or stably transfected human Jurkat cells expressing each of the constructs were stimulated with PMA/Ion for 15 min and then analyzed by flow cytometry to evaluate the expression of MHC-I in the plasma membrane. The results shown in




Fig. 4 (a) EP153R-derived constructs. Representation of the constructs generated from EP153R as indicated in **Materials and methods**. The position of secondary structure elements is indicated (TM: transmembrane, H: alpha-helix and E: beta-strand) and numbered successively, as shown in Fig. 1a. “EP153R”: whole gene; “Lectin C”: sequence from Trp51 to Lys153; “trunc Lectin C”: sequence from Trp51 to Leu148; “R133D”: whole EP153R gene with the mutation Arg133Asp; “R133 K”: whole EP153R gene with the mutation Arg133Lys. (b, c) Effect of different EP153R-derived constructs on human MHC-I expression. Jurkat cells, transiently (b) or stably (c) transfected with pcDNA or different constructions

derived from EP153R (as described in a) were stimulated with PMA/Ion for 15 min and then incubated with human MHC-I (W6/32) antibody before flow cytometry analysis. (d) Effect of different EP153R-derived constructs on porcine SLA-I expression. IPAM cells that were stably transfected with the EP153R-derived constructs were incubated with porcine SLA-I (BL6H4) antibody to detect the expression of these molecules in the plasma membrane by flow cytometry. The level of antigen expression in the plasma membrane is shown (mean \pm S.D. in duplicate samples). (e) mRNA transcription from the EP153R gene was assayed in stably transfected Jurkat cell lines by RT-PCR

Fig. 4b and c reveal a considerable inhibition of surface MHC-I expression in Jurkat cells transfected with either the whole gene (“EP153R”) or with the complete lectin domain (“Lectin C”), while those transfected with the control pcDNA plasmid or with “trunc lectin C” exhibited a similar intensity of MHC-I antigens in the plasma membrane. These results clearly demonstrate the importance of the conformation of the lectin domain of EP153R for the MHC inhibitory function displayed by the viral protein. Moreover, as also shown in Fig. 4, one single substitution of residue 133 (arginine) by aspartic acid (“R133D”) in the whole EP153R gene resulted in MHC-I expression returning to control levels. The corresponding change from arginine to lysine (“R133 K”) maintained the ability of EP153R to down-regulate the expression of MHC-I in the plasma membrane. A similar experiment was performed in IPAM cells that were stably transfected with the EP153R-derived constructs described above, and the same results were obtained (Fig. 4d) as with Jurkat cells (Fig. 4b and c), confirming that the effect of the virus lectin on the MHC-I expression can be accomplished both in transitory and stably transfections, and in different cell lines.

Taking these data together supports our model (Fig. 2), which predicts a possible interaction between the viral lectin EP153R and class I antigens in which the R133 residue, located in the lectin “heads” of the EP153R homodimer (Fig. 2c), should play a critical role in the interaction of both EP153R subunits with the SLA-I molecule.

EP153R impairs the exocytosis, but not the maturation, of human MHC-I antigens

We next explored the mechanism by which EP153R modulates MHC-I expression in the plasma membrane. To achieve this, we first analyzed the kinetics of maturation of MHC-I antigens in human Jurkat cells stably expressing EP153R by determining the resistance of these molecules to endoglycosidase H (Endo H) treatment, which cleaves asparagine-linked mannose-rich oligosaccharides, but not highly processed complex oligosaccharides, from glycoproteins. Proteins correctly processed through the ER and Golgi become resistant to Endo H. Cells were pulse-labeled for 15 min, chased for different times up to 6 h, and then immunoprecipitated with the MHC-I-specific W6/32 antibody. One half of each sample was treated with Endo H enzyme, while the other half was maintained in Endo H reaction buffer and analyzed, after digestion, in polyacrylamide gels. As shown in Fig. 5a, the glycosidase treatment resulted in the total conversion of the immunoprecipitated proteins to a fast-migrating band (compare -/+ Endo H in 0h

chase, Fig. 5a). This result indicates that the entire α -chain of the MHC-I molecule was accessible to the Endo H enzyme. As maturation proceeded, the intensity of the lighter band decreased (chases from 0.5 to 6 h) in favor of the slow-migrating bands. Regarding the effect of EP153R, we could not detect significant changes in the accessibility to Endo H of MHC-I antigens, nor in the rate of MHC synthesis and degradation, either in the presence or in the absence of EP153R (Fig. 5a), thus indicating that the viral lectin does not modulate these events.

The process of exocytosis of human MHC-I antigens was assessed by evaluating the incorporation of new MHC-I molecules into the plasma membrane by flow cytometry. Fig. 5b shows that Jurkat-pcDNA cells had an about 6




Fig. 5 (a) Maturation of human MHC-I molecules. Jurkat cells that were stably transfected with pcDNA or EP153R were pre-stimulated with PMA/Ion, pulse-labeled for 15 min with [³⁵S]methionine-cysteine and chased at 0, 0.5, 2, 4 and 6 h after labeling. Cells were then lysed, immunoprecipitated with human MHC-I (W6/32) antibody and treated either with Endo H enzyme (+) or with buffer alone (-). Proteins were separated by SDS-PAGE and visualized by autoradiography. The corresponding positions of MHC-I molecules that were resistant (Endo H_R) or sensitive (Endo H_S) to Endo H enzyme are indicated. (b, c) Exocytosis of human MHC-I molecules in the presence of EP153R. Jurkat cells that were stably transfected with pcDNA or EP153R were stimulated with PMA/Ion for 15 min and then incubated with an excess of W6/32 monoclonal antibody for 60 min at 4°C. After saturation, cells were washed with PBS and incubated further at 37°C for the times indicated in the figures (b, short-term and c, long-term) before being cooled again to 4°C. Samples were then incubated with W6/32 monoclonal antibody conjugated to FITC to detect the expression of new MHC-I molecules by flow cytometry. The intensity of the antigen expression in the plasma membrane is shown (mean ± S.D. in duplicate samples), representing the results obtained in three independent experiments. The control of EP153R-specific mRNA transcription by RT-PCR in stably transfected Jurkat cell lines is shown in Fig. 3c

times higher level of expression of new MHC-I antigens in the plasma membrane when incubated for up to 60 min at 37°C after saturation with W6/32 antibody, while Jurkat-EP153R cells displayed a very low level of MHC-I expression. The differences amounted more than 10-fold when comparing the levels between EP153R- and pcDNA-transfected cells at 60 min (Fig. 5b). The expected levels of MHC-I expression (with values about 3-fold higher in the absence of EP153R expression, see Fig. 3b) were obtained when incubation after saturation was extended to between 24 and 72 h (Fig. 5c). Taken together, these results clearly indicate that the viral lectin EP153R does not interfere with the synthesis and post-translational modification/degradation of the MHC-I molecules but, most probably, with their appropriate configuration or presentation into the plasma membrane.

EP153R contains an ER retrieval signal and co-localizes with ER markers

The presence of a double lysine motif near the extreme (positions 3, 4 or 5) of the cytoplasmic portion of the molecule has been described in several cellular and viral transmembrane proteins as an ER retrieval signal, targeting them to this subcellular compartment [30]. In the case of the ASFV lectin gene EP153R, the N-terminal extreme

(exposed to the cytoplasmic side) contained two lysines at positions 4 and 5 (Fig. 1a), or three lysines at positions 3, 4 and 5, assuming that the initiator methionine was absent in the mature molecule. To analyze the subcellular localization of the ASFV lectin, Vero cells were transiently transfected with the plasmid pEGFP-C2-EP153R (see [Materials and methods](#)) and analyzed by confocal microscopy after counterstaining with molecular probes specific for ER, Golgi, lysosomes or mitochondria. As shown in Fig. 6, the green fluorescent label of the EGFP-EP153R protein is mainly localized close to the ER marker, and not with any of the other subcellular markers used, suggesting that most of the virus lectin accumulates in the ER when ectopically expressed in transfected cells.

MHC-I expression is also reduced by the presence of EP153R during virus infection and is required the integrity of the lectin domain

To determine whether the ASFV lectin was also able to modulate MHC-I expression during the course of a virus infection, we used macrophage-derived Raw cells transiently transfected with EP153R as a new model (murine) to study the function of the viral protein during either ASFV or vaccinia virus infection. Cells were infected with Δ EP153R, a mutant virus derived from the Vero-adapted




Fig. 6 Expression of the EGFP-EP153R protein. Vero cells that were transiently transfected with the ASFV EP153R gene fused to EGFP were labeled with MitoTracker to stain mitochondria or incubated

with antibodies specific for the cellular ER, Golgi or lysosome as described in [Materials and methods](#), and examined by confocal microscopy

BA71 V strain of ASFV, which lacks the EP153R gene [14], and analyzed at different times after infection by flow cytometry, using specific antibodies against MHC-I. As shown in Fig. 7a, the basal level of MHC-I expression in the plasma membrane was similar in both mock-pcDNA- and mock-EP153R-transfected cells. However, MHC-I levels increased from 4 to 16 h post-infection (hpi) in pcDNA-transfected cells (Fig. 7a, grey bars) compared to EP153R-transfected cells (solid bars), which maintained basal levels of MHC-I expression, both at early and late times during ASFV- Δ EP153R infection. These results

indicate that the presence of EP153R impairs the expression or the accessibility of MHC-I molecules in the cell membrane.

To further demonstrate the importance of the integrity of the lectin C domain in the modulation of MHC-I expression during virus infection, cultures of stably-transfected Raw cells expressing either the whole protein (“EP153R”), the lectin-C domain (“lectin C”), the truncated lectin (“trunc lectin C”) (see Fig. 4a), or the control (“pcDNA”) parental plasmid were infected with either ASFV- Δ EP153R or vaccinia virus at a multiplicity of infection




Fig. 7 Modulation of MHC-I expression by the EP153R gene in virus infections. **(a)** Inhibition of murine MHC-I expression by EP153R. Cultures of Raw cells that were transiently transfected with pcDNA or EP153R were mock-infected or infected with ASFV- Δ EP153R and incubated at the indicated times after infection (hpi) with antibody specific for murine MHC-I antigens to analyze the expression of these molecules in the plasma membrane by flow cytometry (mean \pm S.D. in duplicate samples). **(b)** Effect of different constructs derived from EP153R on murine MHC-I expression. Raw cells that were stably transfected with pcDNA or different EP153R-derived constructs (EP153R, Lectin C or trunc Lectin C) were mock-infected or infected with ASFV- Δ EP153R or vaccinia virus as described in [Materials and methods](#). Cells collected at 18 hpi were incubated with murine MHC-I antibody to detect MHC-I expression in the plasma membrane by flow cytometry. The level of antigen expression is shown (mean \pm S.D. in duplicate samples). **(c)** Modulation of SLA-I expression by siRNA specific for EP153R. IPAM

cells were transfected or not with control (irrelevant) or EP153R-specific siRNA (60 nM) and infected 20 h after transfection with the Uganda 59 isolate of ASFV. At the times indicated, duplicate samples were collected to determine the level of expression of SLA-I (BL6H4) in the plasma membrane by flow cytometry **(c)** and EP153R mRNA transcription by RT-PCR **(d)**. The level of antigen expression is shown (mean \pm S.D.). The results are representative of several experiments (more than six), including infections with other virulent ASFV isolates. **(e)** Modulation of SLA-I expression in porcine cells infected with EP153R-deletion mutants. Cultures of IPAM cells were infected with the parental virus E70 or its corresponding recombinant (ED4) lacking the EP153R gene. Cells collected at 40 hpi were incubated with porcine SLA-I antibodies (BL6H4, 4B7/8 or JM1E3) to analyze the expression of class I antigens (mean \pm S.D. in duplicate samples) in the plasma membrane by flow cytometry. mRNA transcription from the p72 and EP153R genes was measured by RT-PCR **(f)**

(moi) of 3 plaque-forming units (pfu) per cell. MHC-I expression was evaluated by flow cytometry at 18 hpi. Fig. 7b shows that both ASFV and vaccinia virus infection enhanced the levels of MHC-I expression from <60 (mean intensity in mock-infected cultures) to 90–100 in Raw-pcDNA cells. As expected, this enhancement was not observed in Raw-EP153R cells, in agreement with the results shown in Fig. 7a. Moreover, the results obtained in Raw-Lectin C cells were similar to those obtained with the complete EP153R gene (Fig. 7b), with comparable levels of MHC-I expression in either mock-infected or virus-infected cells, thus reinforcing that the lectin C domain is the region of EP153R responsible of the inhibition of MHC-I expression. The preservation of the 3D structure of the lectin domain was found again to be critical for retaining the inhibitory function, since expression of the “trunc lectin C” construct yielded similar results to those obtained for control Raw-pcDNA cells (Fig. 7b).

To further corroborate the role of the viral lectin gene in ASFV infection, porcine IPAM cells were transfected with a specific siRNA against EP153R (60 nM). Twenty hours after siRNA transfection, cells were infected with the ASFV-Uganda 59 isolate (moi of 3 pfu per cell) and, at different times after infection, collected to analyze the effect of silencing EP153R on SLA-I expression. As shown in Fig. 7c, the level of SLA-I expression was not importantly affected by the transfection with control siRNA, either before (Mock) or after ASFV infection. However, cultures transfected with EP153 siRNA exhibited a significantly higher level of expression of SLA-I induced by ASFV, especially at late times during the infection cycle (16 hpi). In parallel, the inhibition of EP153R mRNA transcription was assessed by RT-PCR. The results obtained (Fig. 7d) revealed that EP153R mRNA was detected in the infected cells at 6 hpi, with similar levels in the untransfected cultures (white bars in c) and those transfected with the control siRNA (grey bars in c), while an evident decrease in transcription was found in the samples silenced with the siRNA specific for EP153R (solid bars in c), in coincidence with the higher expression of MHC-I antigens observed in these cells.

A second approach for determining the role of EP153R during virus infection took advantage of the ASFV recombinant with the viral lectin gene deleted from the E70 isolate generated in our laboratory. IPAM cells were infected with the virulent ASFV isolate E70 or its corresponding deletion mutant for the EP153R gene (ED4) and analyzed at 40 hpi for SLA-I expression by flow cytometry. Three monoclonal antibodies specific for porcine SLA-I antigens were used in this experiment (Fig. 7e), revealing a higher expression of these molecules in the cultures infected with the deletion mutant under conditions in which the EP153R gene was not transcribed (Fig. 7f).

Discussion

We have previously described several features of the amino acid sequence of the ASFV protein pEP153R and the involvement of this viral protein in the hemadsorption and apoptotic processes observed in ASFV-infected cells [4, 14]. The homology of the predicted sequence of pEP153R with several C-type lectin molecules, such as CD94, Ly49A and CD69 [5–7], prompted us to build a model of the 3D structure of the viral lectin using information based on the crystallographic coordinates of these molecules in available databases. According to this information, the predicted structure of the EP153R protein comprises a cytoplasmic unstructured N-terminal segment, followed by a transmembrane region preceding the C-type lectin domain. This last domain displays a 3D structure that is maintained by the presence of several disulfide bonds between Cys residues conserved in the aligned sequences (the unstructured loop present in the other lectin molecules is absent in EP153R). The dimeric nature of the crystallized antigens used as templates helped us to define a dimer structure for EP153R. This was based on the complementarity of the helix H3 and beta strand E1 structural elements and on the increased stability derived from the interacting polar residues in the transmembrane helix H1-TM. Other putative disulfide bonds between neighboring Cys residues in the monomers should help to further stabilize the dimer structure.

A possible model for the interaction between MHC-I antigens and the EP153R dimer was then generated. To do this, we used the arrangement described previously for the interaction between the NK cell C-type lectin-like receptor NKG2D and its MHC-I-like ligand ULBP3 as a template [28] and predicted reasonable electrostatic complementarities and stability of the complex. This modeled interaction between the EP153R dimer and MHC class I antigens encouraged us to predict the role of the viral protein in the modulation of MHC-I expression in living cells. Two reports have established the fine structure of the Ly49A-H-2K^b complex [31] and the structural basis of the recognition of HLA-E molecules by the heterodimer NKG2A/CD94 as well as its specific binding to the viral MHC-homologue protein UL18 from cytomegalovirus [32]. Although the geometry of the two interactions is not the same, and they are both different from that exhibited by the template [28] used in this work for the model of the EP153R-SLA-I complex, in all these cases, they have been described [32] as part of a viral immunoevasion strategy.

We have used three different cellular models (porcine, murine and human) to determine the effect of the EP153R gene on the modulation of MHC-I expression. IPAM cells, derived from swine alveolar macrophages, were chosen to analyze the effect of the ASFV lectin gene in a porcine cell

environment provided by an established line suitable for transfection and derived from the target cell for “in vivo” ASFV infection. In this model, we detected down-regulation of the expression of SLA-I molecules in the plasma membrane of the IPAM cells in the presence of EP153R, while the expression of class II antigens was not affected by the ASFV lectin.

To gain further insight into the role of the EP153R gene in MHC-I expression, we used human and murine cell lines. This allowed us to define the effect of the gene on heterologous expression in models in which the available commercial tools were of higher specificity and sensitivity (for example, more than 10 antibodies specific for different subclasses of human MHC-I can be purchased from Serotec, Santa Cruz or AbNova, while only one (JM1E3) specific for porcine SLA-I antigen is available from these suppliers). Successful transfection of both Jurkat and Raw cells with different EP153R-derived constructs resulted in the generation of established cell lines expressing the corresponding protein. The use of the Jurkat cell line allowed us to confirm that the presence of EP153R in stably-transfected cells also specifically reduced the expression of human MHC-I in the plasma membrane, since another cell-surface molecule like ICAM-1 was not affected by the expression of the viral gene. Moreover, the expression of those antigens also decreased in the presence of either the whole gene (“EP153R”) or the EP153R C-type lectin domain (“Lectin C”), while “trunc Lectin C”, which contains a deletion in the C-terminal sequence of Lectin C, did not modulate MHC-I expression in Jurkat cells stimulated with PMA/Ion. This was probably because of the large conformational changes induced in the lectin C domain by the deletion of the E6 region (F149 to K153, including the residue C151, a cysteine that may be involved in a disulfide bond with C97) of the EP153R molecule. The use of two EP153R-derived constructs with single substitutions of residue R133 for equivalent (K) or antagonistic (D) amino acids in terms of electrostatic charge lends significant support to the predicted model of the interaction of EP153R with the MHC-I antigens: the down-modulation of MHC-I expression in the plasma membrane by the viral lectin was prevented by a single change from R to D at residue 133. It is interesting to note that this is a highly conserved residue among many ASFV isolates [33], and we anticipated that this position, postulated to be in the lectin “heads” of the EP153R dimerized structure, was critically involved in the electrostatic complementarity that is predicted to be important in the interaction of both subunits of the EP153R homodimer with the groove region of the heavy chain of the SLA-I molecule.

Regarding the murine cellular model, the level of MHC-I expression in Raw cells was not affected by transfection with the EP153R gene. However, stably transfected Raw

macrophages showed an increased level of MHC-I expression after infection with either ASFV Δ EP153R mutant virus or vaccinia virus, which was prevented by the expression of either the whole EP153R gene or the “Lectin-C” construct. In contrast, deletion of the sequence F149-K153 from the E6 region of EP153R resulted in a construct (“trunc Lectin C”) that, as in the case of Jurkat cells, did not modulate the expression of MHC-I when used to transfect Raw cells. This suggests that the preservation of the 3D structure of the lectin domain is critical for establishing the appropriate interaction between EP153R and the MHC-I molecule and that it should be also involved in the process of virus infection.

In order to analyze the role of the EP153R gene during ASFV infection, we used two approaches, interference with siRNA and infection with virus deletion mutants. In the first approach, IPAM cells, a line of porcine macrophages that can be infected with several virulent and attenuated ASFV isolates, were infected with a virulent (Uganda 59) isolate after silencing EP153R gene transcription with a specific siRNA. The work presented in this paper indicates that a partial silencing of EP153R gene transcription results in a moderate increase of the levels of SLA-I expression on the plasma membrane of ASFV-infected IPAM cells, thus indicating that the ASFV lectin also modulates MHC-I expression in *in vivo* infections. For the second approach, we used an ASFV recombinant generated in our laboratory from the E70 isolate of ASFV with the EP153R gene inactivated (ED4) to infect IPAM porcine cells. In this case, we did not use the BA71 V isolate and its EP153R-deletion mutant (DEP), since they produce a very limited infection in IPAM cell cultures (unpublished observations). Our results revealed that the expression of SLA-I antigens in the plasma membrane was reduced in cells infected with the parental E70 strain as compared with those infected with the corresponding EP153R-deletion mutant ED4. The effect of the ASFV EP153R lectin gene, however, was less remarkable when analyzed during ASFV infection of porcine cells than in heterologous expression in EP153R-transfected cell lines. Differences in the expression levels of the viral lectin gene in each system and/or in the specificity/sensitivity of the available antibodies to recognize the particular subclass of SLA-I involved in the interaction with EP153R, might account for these divergences.

Regarding the mechanism by which the expression of MHC-I was reduced in the presence of EP153R, we studied the possibility of an impairment in the process of maturation and exocytosis of MHC-I molecules in the human model. Our results establish that the synthesis and glycosylation of MHC-I molecules proceeded normally, while exocytosis of mature molecules in the plasma membrane was severely affected in Jurkat cells transfected with the EP153R gene when compared with control pcDNA-transfected

cultures. As MHC-I synthesis or degradation was not affected by the expression of EP153R, we propose that the low levels of surface MHC-I antigens observed in the presence of the viral protein might be a consequence of the misfolding or retention of MHC-I molecules in the Golgi or ER compartments. Another possibility is that the MHC-I molecules emerging in the plasma membrane are not recognized by the specific antibodies when they are associated with the viral protein EP153R. It is also tempting to suggest a mechanism for the ASFV lectin similar to that described for adenovirus E19 protein [1], whose ability to interact with murine and human MHC-I molecules results in their retention in the ER, mediated by an ER retention motif. In fact, the analysis of the sequence of the EP153R gene revealed the presence of a similar motif, with three lysines in positions 3, 4 and 5 in the cytoplasmic end of the molecule, which might direct the protein to this subcellular compartment, as described for several cellular and viral transmembrane proteins [30]. The colocalization of the EP153R protein fused to a GFP tag with ER markers in transfected Vero cells by confocal microscopy also supported the possibility that the ASFV lectin can display a similar location to that of other viral (adeno E19) and cellular (calnexin and calreticulin) lectins that are known to interact with the heavy chain of MHC-I molecules before their association with β 2-microglobulin in the ER. However, further experiments are needed to explain the effective down-regulation of MHC-I antigens obtained in transfections with the “Lectin C” construct, in which the intracellular amino terminal region of EP153R was eliminated. Interestingly, the absence of the ER retention signal in this construct indicated that the dilysine motif was not needed for the reduction of MHC-I expression on the cell surface. Nevertheless, it is not excluded that the interaction between EP153R and MHC-I must occur in the ER, since other single-pass transmembrane proteins in the ER, like tapasin or tyrosinase, have been shown to maintain their localization to the ER in constructs lacking the transmembrane domain and the cytoplasmic tail (which includes the ER retrieval motif) [34, 35]. Alternative mechanisms for affecting MHC-I expression, such as the induction of misfolding (with impaired recognition by the specific antibodies) or the inhibition of peptide loading described for truncated versions of adenovirus E19 protein without its ER retention signal [36], could also be exploited by the ASFV lectin.

The absence of a vaccine available for ASF is a major problem for the control of the disease. However, protective immunity against homologous virus has been described in pigs surviving viral infection [37], most probably involving both humoral and cellular immunity. Although ASFV neutralizing antibodies directed against virus proteins have been reported, they are not sufficient for protection, forcing

CTLs and NK cells to have a role in the protective immune response to ASFV infection (reviewed in ref. 3). An efficient cellular response could be related to the persistent and non-lethal disease observed in wild hosts and to the attenuated forms also detected in domestic pigs. Besides, reduced expression of the MHC-I antigens in the plasma membrane of an infected cell may produce both an anomalous presentation of the viral peptides to CTLs and changes in the NK cell response, suggesting that the deletion of the ASFV EP153R gene may result in a more attenuated virus, which must induce a more efficient cellular immune response.

In conclusion, in this report, we have demonstrated a role for the ASFV lectin pEP153R in the modulation of MHC-I expression in the cell membrane. This is probably mediated by the retention of correctly glycosylated MHC-I molecules in subcellular compartments and provides a new mechanism for ASFV evasion of host antiviral responses.

Acknowledgements We are grateful to Begoña Galocha for experimental help and discussions. We also thank Biomol-Informatics SL (www.biomol-informatics.com) for bioinformatics consulting. This work was supported by grants from the Spanish Ministerio de Ciencia y Tecnología (BFU2007-63110/BMC), from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement KBBE- 211691- ASFRISK and from Laboratorios del Dr. Esteve, SA, and also by institutional grants from the Fundación Ramón Areces and Banco Santander Central Hispano. C.H. and A.G.G. also acknowledge financial support from the Centro de Investigación en Sanidad Animal (CISA).

References

1. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL (2000) Viral subversion of the immune system. *Annu Rev Immunol* 18:861–926
2. Lin A, Xu H, Yan W (2007) Modulation of hla expression in human cytomegalovirus immune evasion. *Cell Mol Immunol* 4(2):91–98
3. Tulman ER, Delhon GA, Ku BK, Rock DL (2009) African swine fever virus. *Curr Top Microbiol Immunol* 328:43–87
4. Hurtado C, Granja AG, Bustos MJ, Nogal ML, Gonzalez de Buitrago G, de Yébenes VG, Salas ML, Revilla Y, Carrascosa AL (2004) The c-type lectin homologue gene (ep153r) of african swine fever virus inhibits apoptosis both in virus infection and in heterologous expression. *Virology* 326(1):160–170
5. Boyington JC, Riaz AN, Patamawenu A, Coligan JE, Brooks AG, Sun PD (1999) Structure of cd94 reveals a novel c-type lectin fold: Implications for the nk cell-associated cd94/nkg2 receptors. *Immunity* 10(1):75–82
6. Tormo J, Natarajan K, Margulies DH, Mariuzza RA (1999) Crystal structure of a lectin-like natural killer cell receptor bound to its mhc class i ligand. *Nature* 402(6762):623–631
7. Llera AS, Viedma F, Sanchez-Madrid F, Tormo J (2001) Crystal structure of the c-type lectin-like domain from the human hematopoietic cell receptor cd69. *J Biol Chem* 276(10):7312–7319
8. Weingartl HM, Sabara M, Pasick J, van Moorlehem E, Babiuk L (2002) Continuous porcine cell lines developed from alveolar

- macrophages: Partial characterization and virus susceptibility. *J Virol Methods* 104(2):203–216
9. Carrascosa AL, Santaren JF, Vinuela E (1982) Production and titration of african swine fever virus in porcine alveolar macrophages. *J Virol Methods* 3(6):303–310
 10. Enjuanes L, Carrascosa AL, Moreno MA, Vinuela E (1976) Titration of african swine fever (asf) virus. *J Gen Virol* 32(3):471–477
 11. Garcia-Barreno B, Sanz A, Nogal ML, Vinuela E, Enjuanes L (1986) Monoclonal antibodies of african swine fever virus: Antigenic differences among field virus isolates and viruses passaged in cell culture. *J Virol* 58(2):385–392
 12. Salguero FJ, Gil S, Revilla Y, Gallardo C, Arias M, Martins C (2008) Cytokine mRNA expression and pathological findings in pigs inoculated with african swine fever virus (e-70) deleted on a238 l. *Vet Immunol Immunopathol* 124(1–2):107–119
 13. Hurtado C, Bustos MJ, Carrascosa AL (2010) The use of cos-1 cells for studies of field and laboratory african swine fever virus samples. *J Virol Methods* 164(1–2):131–134
 14. Galindo I, Almazán F, Bustos MJ, Viñuela E, Carrascosa AL (2000) African swine fever virus ep153r open reading frame encodes a glycoprotein involved in the hemadsorption of infected cells. *Virology* 266(2):340–351
 15. Rodriguez JM, Almazan F, Vinuela E, Rodriguez JF (1992) Genetic manipulation of african swine fever virus: Construction of recombinant viruses expressing the beta-galactosidase gene. *Virology* 188(1):67–76
 16. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A (1978) Production of monoclonal antibodies to group a erythrocytes, hla and other human cell surface antigens—new tools for genetic analysis. *Cell* 14(1):9–20
 17. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. *J Mol Biol* 215(3):403–410
 18. Thompson JD, Higgins DG, Gibson TJ (1994) Clustal w: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 22(22):4673–4680
 19. Notredame C, Higgins DG, Heringa J (2000) T-coffee: A novel method for fast and accurate multiple sequence alignment. *J Mol Biol* 302(1):205–217
 20. Kelley LA, Sternberg MJ (2009) Protein structure prediction on the web: A case study using the phyre server. *Nat Protoc* 4(3):363–371
 21. Kelley LA, MacCallum RM, Sternberg MJ (2000) Enhanced genome annotation using structural profiles in the program 3d-ppsm. *J Mol Biol* 299(2):499–520
 22. Andreeva A, Howorth D, Brenner SE, Hubbard TJ, Chothia C, Murzin AG (2004) Scop database in 2004: Refinements integrate structure and sequence family data. *Nucleic Acids Res* 32 (Database issue):D226–229
 23. Holm L, Park J (2000) Dalilite workbench for protein structure comparison. *Bioinformatics* 16(6):566–567
 24. Velloso LM, Michaelsson J, Ljunggren HG, Schneider G, Achour A (2004) Determination of structural principles underlying three different modes of lymphocytic choriomeningitis virus escape from c1l recognition. *J Immunol* 172(9):5504–5511
 25. Guex N, Diemand A, Peitsch MC (1999) Protein modelling for all. *Trends Biochem Sci* 24(9):364–367
 26. Peitsch MC (1996) Promod and swiss-model: Internet-based tools for automated comparative protein modelling. *Biochem Soc Trans* 24(1):274–279
 27. Schwede T, Kopp J, Guex N, Peitsch MC (2003) Swiss-model: An automated protein homology-modeling server. *Nucleic Acids Res* 31(13):3381–3385
 28. Radaev S, Rostro B, Brooks AG, Colonna M, Sun PD (2001) Conformational plasticity revealed by the cocrystal structure of nkg2d and its class i mhc-like ligand ulbp3. *Immunity* 15(6):1039–1049
 29. Guex N, Peitsch MC (1997) Swiss-model and the swiss-pdbviewer: An environment for comparative protein modeling. *Electrophoresis* 18(15):2714–2723
 30. Jackson MR, Nilsson T, Peterson PA (1990) Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum. *Embo J* 9(10):3153–3162
 31. Deng L, Cho S, Malchiodi EL, Kerzic MC, Dam J, Mariuzza RA (2008) Molecular architecture of the major histocompatibility complex class i-binding site of ly49 natural killer cell receptors. *J Biol Chem* 283(24):16840–16849
 32. Kaiser BK, Pizarro JC, Kerns J, Strong RK (2008) Structural basis for nkg2a/cd94 recognition of hla-e. *Proc Natl Acad Sci U S A* 105(18):6696–6701
 33. Neilan JG, Borca MV, Lu Z, Kutish GF, Kleiboeker SB, Carrillo C, Zsak L, Rock DL (1999) An african swine fever virus orf with similarity to c-type lectins is non-essential for growth in swine macrophages in vitro and for virus virulence in domestic swine. *J Gen Virol* 80(Pt 10):2693–2697
 34. Everett MW, Edidin M (2007) Tapasin increases efficiency of mhc i assembly in the endoplasmic reticulum but does not affect mhc i stability at the cell surface. *J Immunol* 179(11):7646–7652
 35. Popescu CI, Paduraru C, Dwek RA, Petrescu SM (2005) Soluble tyrosinase is an endoplasmic reticulum (er)-associated degradation substrate retained in the er by calreticulin and bip/grp78 and not calnexin. *J Biol Chem* 280(14):13833–13840
 36. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM (1999) Cutting edge: Adenovirus e19 has two mechanisms for affecting class i mhc expression. *J Immunol* 162(9):5049–5052
 37. Ruiz Gonzalvo F, Carnero ME, Caballero C, Martinez J (1986) Inhibition of african swine fever infection in the presence of immune sera in vivo and in vitro. *Am J Vet Res* 47(6):1249–1252